Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.52 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.52 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.43 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953915 | 1.00 | TRIM24 (0.52) | TRIM24TRIM33IDH1BTKNFE2L2 | |
| SCHEMBL30989469 | 0.87 | TRIM24 (0.47) | TRIM24TRIM33IDH1BTKNFE2L2 | |
| SCHEMBL16096639 | 0.82 | TRIM24 (0.46) | TRIM24TRIM33IDH1BTKNFE2L2 | |
| SCHEMBL6629613 | 0.82 | IDH1 (0.46) | TRIM24TRIM33IDH1BTKNFE2L2 | |
| SCHEMBL871969 | 0.81 | ALDH1A1 (0.51) | TRIM24TRIM33NPC1LMNAALDH1A1 | |
| SCHEMBL29953656 | 0.81 | ALDH1A1 (0.51) | TRIM24TRIM33NPC1LMNAALDH1A1 | |
| SCHEMBL23516654 | 0.80 | IDH1 (0.44) | TRIM24TRIM33IDH1BTKNFE2L2 | |
| SCHEMBL28151579 | 0.80 | IDH1 (0.44) | TRIM24TRIM33IDH1BTKNFE2L2 | |
| SCHEMBL28800617 | 0.80 | IDH1 (0.44) | TRIM24TRIM33IDH1BTKNFE2L2 | |
| SCHEMBL2600013 | 0.79 | TRIM24 (0.47) | TRIM24TRIM33NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116867782-A | Pyrazole amide derivative | 豪夫迈·罗氏有限公司 | 2023-10-10 | — | — | CN | claimed |
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| CN-102015993-B | Encapsulated benefit agent | UNILEVER PLC | 2013-03-27 | — | — | CN | claimed |
| CN-102015993-A | Encapsulated benefit agent | UNILEVER PLC | 2011-04-13 | — | — | CN | claimed |
| EP-2245132-A1 | ENCAPSULATED BENEFIT AGENT | Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) | 2010-11-03 | — | — | EP | claimed |
| WO-2009103576-A1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC (GB) | 2009-08-27 | — | — | WO | claimed |
| EP-3820860-B1 | PYRIDAZINE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025106482-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) | 2025-05-22 | — | — | WO | disclosed |
| CN-119731185-A | Synthesis of substituted 1-aryl-1 '-heteroaryl compounds and substituted 1,1' -bisheteroaryl compounds and analogs thereof | 爱彼特生物制药公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-4476204-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | Theras, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118946555-A | Compounds having T-structures formed by at least four rings for use in the treatment of cancer and other indications | 瑟拉斯有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-5212317-A | Methods and intermediates for the assymmetric synthesis of camptothecin and camptothecin analogs | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-05-18 | — | — | US | disclosed |
| US-5200524-A | Camptothecin intermediates and method of making same | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-04-06 | — | — | US | disclosed |
| US-5191082-A | Camptothecin intermediate and method of making camptothecin intermediates | NORTH CAROLINA STATE UNIVERSITY (US) | 1993-03-02 | — | — | US | disclosed |
| CN-1067656-A | 2 of aminomethyl replacement, the 3-dihydropyrane is [2,3-b] pyridines also, preparation method and the application in medicine | BAYER AG (DE) | 1993-01-06 | — | — | CN | disclosed |
| EP-0519291-A1 | Amino-methyl substituted 2,3-Dihydropyrano (2,3-b) pyridines, process for their preparation and their use in medicines | BAYER AG (DE) | 1992-12-23 | — | — | EP | disclosed |
| US-5162532-A | INTERMEDIATES AND METHOD OF MAKING CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS | NORTH CAROLINA STATE UNIVERSITY (US) | 1992-11-10 | — | — | US | disclosed |
| WO-1992011263-A1 | METHOD OF MAKING CAMPTOTHECIN AND CAMPTOTHECIN ANALOGS | NORTH CAROLINA STATE UNIVERSITY (US) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | TRIM24 2074/4885TRIM33 3195/4885IDH1 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.